Medical Advocates
Atazanavir (Reyataz)
 
Journal Citations

General Reports                   Therapeutic Strategies
 In Vitro Studies                    Adherence
 Dosage
 Pharmacokinetics
 Resistance
 Drug/Drug Interactions
 Drug Comparison Studies
 Efficacy
 Diagnostics/Monitoring
 Adverse Events
 Viral Dynamics
 Adherence

  
Atazanavir Main Page New/Newsworthy Home Page      
Last updated:  September 02, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
 
Comparison of ABC Transporter Modulation by Atazanavir in Lymphocytes and Human Brain Endothelial Cells:
ABC Transporters Are Involved in the Atazanavir-Limited Passage across an in Vitro Human Model of the
Blood-Brain Barrier.
Bousquet L, Roucairol C, Hembury A, et al 
AIDS Res Hum Retroviruses. 2008 Aug 26.
 Abstract
 
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors
atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
 Dubé MP, Shen C, Greenwald M, Mather KJ.
Clin Infect Dis. 2008 Aug 15;47(4):567-74.
 Abstract
 
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous
and omental preadipocytes.
 Jones SP, Waitt C, Sutton R, Back DJ, Pirmohamed M.
AIDS. 2008 Jul 11;22(11):1293-8.
 Abstract
 
The Effect of Atazanavir and Atazanavir/Ritonavir on UDP-Glucuronosyltransferase Using Lamotrigine
as a Phenotypic Probe.
 Burger D, Huisman A, Van Ewijk N, et al 
Clin Pharmacol Ther. 2008 Jun 4.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based
combination antiretroviral regimen.
 Colafigli M, Di Giambenedetto S, Bracciale L 
HIV Med. 2008 Jan 21
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
The Genotypic Inhibitory Quotient: A Predictive Factor of Atazanavir Response in HIV-1-Infected
Treatment-Experienced Patients.
 Solas C, Colson P, Ravaux I, et al
 J Acquir Immune Defic Syndr. 2008 Jan 11
Abstract
 
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients
receiving Atazanavir.
 Vergani B, Cicero ML, Vigano' O, et al
J Clin Virol. 2007 Nov 13;
 Abstract
 
HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death
by Triggering Endoplasmic Reticulum Stress.
 Pyrko P, Kardosh A, Wang W, et al 
Cancer Res. 2007 Nov 15;67(22):10920-10928
Abstract
 
Atazanavir: simplicity and convenience in different scenarios.
 Perez-Elias MJ.
Expert Opin Pharmacother. 2007 Apr;8(5):689-700.
Abstract
 
FULL TEXT PDF ARTICLE
 Pharmaceutical Approach to HIV Protease Inhibitor Atazanavir for Bioavailability
Enhancement Based on Solid Dispersion System.
 Fukushima K, Terasaka S, Haraya K, et al
Biol Pharm Bull. 2007 Apr;30(4):733-8.
 Paper
 
Penetration of atazanavir in seminal plasma of men infected with HIV-1.
 van Leeuwen E, Ter Heine R, van der Veen F, et al 
Antimicrob Agents Chemother. 2006 Oct 30;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion
in HIV-positive patients.
 Busti AJ, Tsikouris JP, Peeters MJ, et al 
HIV Med. 2006 Jul;7(5):317-22.
 Abstract|
 
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity:
demonstrable  differences in vitro and clinically.
 Noor MA, Flint OP, Maa JF, Parker RA.  
AIDS. 2006 Sep 11;20(14):1813-21.
 Abstract
 
Review of atazanavir: a novel HIV protease inhibitor.
 Fuster D, Clotet B.
Expert Opin Pharmacother. 2005 Aug;6(9):1565-72.
 Abstract
 
Atazanavir for the treatment of human immunodeficiency virus infection.
 Busti AJ, Hall RG, Margolis DM.
Pharmacotherapy. 2004 Dec;24(12):1732-47.
Abstract
 
Atazanavir
Orrick JJ, Steinhart CR.
Ann Pharmacother. 2004 Sep 7
Abstract

Atazanavir: New Option for Treatment of HIV Infection.
 Havlir DV, O'Marro SD.
Clin Infect Dis. 2004 Jun 1;38(11):1599-604
 Abstract
In Vitro Studies
       
 

Atazanavir: Effects on P-gp transport and CYP3A metabolism in vitro.
 Perloff ES, Duan SX, Skolnik PR, et al 
Drug Metab Dispos. 2005 Mar 11;
 Abstract
Dosage Studies
       
  Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in
antiretroviral-naive subjects: 48-week results.
 Murphy RL, Sanne I, Cahn P, et al
AIDS. 2003 Dec 5;17(18):2603-14.
Abstract
Pharmacokinetics
       
 
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by
gender-related co-factors.
 von Hentig N, Babacan E, Lennemann T, et al
 J Antimicrob Chemother. 2008 May 13
Abstract
 
Effects of Acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and
ritonavir-boosted atazanavir.
Klein CE, Chiu YL, Cai Y, et al
Clin Pharmacol. 2008 May;48(5):553-62.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Factors associated with altered pharmacokinetics in substance users and
non-substance users receiving lopinavir and atazanavir.
 Higgins N, Zingman BS, Slish J, et al
Am J Addict. 2007 Nov-Dec;16(6):488-94.
 Abstract
 
WEEK-IN-REVIEW FEATURED REPORT
 Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and
Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection - Study ATN056.
 Kiser JJ, Fletcher CV, Flynn PM, et al 
Antimicrob Agents Chemother. 2007 Nov 19;
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Beneficial Pharmacokinetic Interaction Between Atazanavir and Lopinavir/Ritonavir.
 Pham PA, Flexner CW, Parsons T, et al 
J Acquir Immune Defic Syndr. 2007 Mar 29;
 Abstract

 A WEEK-IN-REVIEW FEATURED REPORT
Population pharmacokinetics of atazanavir in patients with human immunodeficiency
virus infection.
 Colombo S, Buclin T, Cavassini M, et al 
Antimicrob Agents Chemother. 2006 Aug 28;
 Abstract
 
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions
score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I, Breilh D, Ragnaud JM, et al  
Antivir Ther. 2006;11(4):421-9
 Abstract
 
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics
in HIV-infected patients.
 Dailly E, Tribut O, Tattevin P, et  al
Eur J Clin Pharmacol. 2006 Jun 9;
 Abstract
 
Steady-state pharmacokinetics of atazanavir given alone or in combination with
saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
 Seminari E, Guffanti M, Villani P, et al 
Eur J Clin Pharmacol. 2005 Jul 23;
 Abstract
 
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals
receiving highly active antiretroviral therapy.
 Winston A, Bloch M, Carr A,  et al  
J Antimicrob Chemother. 2005 Jul 4
 Abstract

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in
HIV-seronegative healthy adults.
 Noor MA, Parker RA, O'mara E, et al 
AIDS. 2004 Nov 5;18(16):2137-2144.
 Abstract
Resistance
       
 
The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to
other protease inhibitorsin multiple mutational contexts.
 Sista P, Wasikowski B, Lecocq P, et al 
J Clin Virol. 2008 May 9
Abstract
 
The Genotypic Inhibitory Quotient: A Predictive Factor of Atazanavir Response in HIV-1-Infected
Treatment-Experienced Patients.
Solas C, Colson P, Ravaux I, et al
J Acquir Immune Defic Syndr. 2008 Jan 11
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
 Stebbing J, Nathan B, Jones R, et al  
AIDS. 2007 Aug 20;21(13):1826-8.
Abstract
 
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir
in patients with HIV.
Ma Q, Brazeau D, Zingman BS, et al  
Pharmacogenomics. 2007 Mar;8(3):227-235.
Abstract
 
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions
score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I, Breilh D, Ragnaud JM, et al  
Antivir Ther. 2006;11(4):421-9
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-
experienced patients.
 Vora S, Marcelin AG, Gunthard HF, Flandre P, et al  
AIDS. 2006 Jan 2;20(1):35-40
 Abstract
 
Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of
Increased Susceptibility to Other Protease Inhibitors in a Variety of Human
Immunodeficiency Virus Type 1 Genetic Backbones.
 Weinheimer S, Discotto L, Friborg J, et al
Antimicrob Agents Chemother. 2005 Sep;49(9):3816-24.
 Abstract

Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in
Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens.
Colonno R, Rose R, McLaren C, et al 
J Infect Dis. 2004 May 15;189(10):1802-10.
Abstract
Cross Resistance
       
Protease Inhibitors
 
 
Molecular Basis for Increased Susceptibility of Isolates with Atazanavir
Resistance-Conferring Substitution I50L to Other Protease Inhibitors.
 Yanchunas J Jr, Langley DR, et al   
Antimicrob Agents Chemother. 2005 Sep;49(9):3825-32.
 Abstract
Viral Dynamics
       
 
Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker,
not significantly different in HIV observational database study.
Keiser PH, Nassar N.
Int J STD AIDS. 2008 Aug;19(8):561-2
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
 Stebbing J, Nathan B, Jones R, et al  
 AIDS. 2007 Aug 20;21(13):1826-8.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions
score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I, Breilh D, Ragnaud JM, et al  
Antivir Ther. 2006;11(4):421-9
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in
treatment-experienced patients.
Naeger LK, Struble KA.
AIDS. 2006 Apr 4;20(6):847-53
 Abstract
Drug Comparison Studies
       
Atazanavir vs Efavirenz
 
  Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With
Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV.
 Squires K, Lazzarin A, Gatell JM 
J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-1019
 Abstract
 
Atazanavir vs Fosamprenavir
 
  FULL TEXT PDF ARTICLE
Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus
tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Smith KY, Weinberg WG, Dejesus E, et aL
AIDS Res Ther. 2008 Mar 28;5(1):5
Paper

Atazanavir vs Lopinavir/Ritonavir
 
 
A WEEK IN REVIEW FEATURED REPORT
 Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic
interaction and predictors of drug exposure.
 Di Giambenedetto S, De Luca A, Villani P, et al
HIV Med. 2008 Apr;9(4):239-45.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with
multiple virologic failures.
 Johnson M, Grinsztejn B, Rodriguez C, et al 
AIDS. 2006 Mar 21;20(5):711-718.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor
failure: a randomized multinational trial.
 Cohen C, Nieto-Cisneros L, Zala C, et al   
 Curr Med Res Opin. 2005 Oct;21(10):1683-92.
 Abstract
Diagnostics/Monitoring
       
 
Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection.
 Cattaneo D, Maggiolo F, Ripamonti D, Perico N.  
J Chromatogr Sci. 2008 Jul;46(6):485-9.
 Abstract
 
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir,
and 11 other antiretroviral agents in plasma of HIV-infected patients.
 D'Avolio A, Siccardi M, Sciandra M, et al
 J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 7;
Abstract
 
Monitoring Atazanavir Concentrations With Boosted or Unboosted Regimens in
HIV-Infected Patients in Routine Clinical Practice.
 Moltó J, Santos JR, Valle M, et al  
Ther Drug Monit. 2007 Oct;29(5):648-651.
 Abstract
 
Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir
Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring.
 Slish J, Ma Q, Zingman BS, et al 
Ther Drug Monit. 2007 Oct;29(5):560-565.
 Abstract
 
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
 Cleijsen RM, van de Ende ME, Kroon FP, et al
J Antimicrob Chemother. 2007 Aug 17;
 Abstract
 
Integration of Atazanavir into an Existing Liquid Chromatography UV Method for Protease
Inhibitors: Validation and Application.
 Keil K, Hochreitter J, Difrancesco R, et al
Ther Drug Monit. 2007 Feb;29(1):103-109.
 Abstract
 
A quantitative immunoassay for plasma and intracellular atazanavir: studies of drug
accumulation in cultured T-cells.
 Roucairol C, Azoulay S, Nevers MC, et al 
Antimicrob Agents Chemother. 2006 Nov 20;
 Abstract
 
Full Validation of an Analytical Method for the HIV-Protease Inhibitor Atazanavir in Combination
With 8 Other Antiretroviral Agents and its Applicability to Therapeutic Drug Monitoring.
Rezk NL, Crutchley RD, Yeh RF, Kashuba AD.
Ther Drug Monit. 2006 Aug;28(4):517-25.
 Abstract
 
Simple determination of the HIV protease inhibitor atazanavir in human plasma
by high-performance liquid chromatography with UV detection.
Loregian A, Pagni S, Ballarin E, et al
 J Pharm Biomed Anal. 2006 Jun 7;

Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
 Sparidans RW, Dost F, Crommentuyn KM, et al  
Biomed Chromatogr. 2005 Jun 14;
Abstract
 
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after
solid-phase extraction.
 Colombo S, Guignard N, Marzolini C, et al  
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 15;810(1):25-34.
 Abstract
 
Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir
in human plasma by high-performance liquid chromatography coupled with electrospray
ionization tandem mass spectrometry.
 Crommentuyn KM, Rosing H, Hillebrand MJ, et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):359-67
 Abstract
 
Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV
protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells
(PBMC): practical approaches to PBMC preparation and PBMC assay design for high-
throughput analysis.
Jemal M, Rao S, Gatz M, Whigan D. 
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):273-89
 Abstract
 
Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human
plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase
extraction.
Schuster A, Burzawa S, Jemal M, et al.
Chromatogr B Analyt Technol Biomed Life Sci 2003 May25;788(2):377-86
 Abstract
 
Adverse Events
       
 
Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in
HIV-infected persons: Randomized controlled trial.
 Flammer AJ, T T Vo N, Ledergerber B, et al
 Heart. 2008 Jul 24.
 Abstract
 
Case presentation: nephrolithiasis in a patient treated with atazanavir.
 Savini C, James C, Wilson S, et al 
J Assoc Nurses AIDS Care. 2008 May-Jun;19(3):225-7."
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients
co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al 
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
Urolithiasis in HIV-positive patients treated with atazanavir
 Couzigou C, Daudon M, Meynard JL,  
Clin Infect Dis. 2007 Oct 15;45(8):e105-8
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz,
lopinavir/ritonavir and atazanavir.
 Bernal E, Masiá M, Padilla S, et al
Med Clin (Barc). 2007 Jul 14;129(7):252-4.
 Abstract
 
Cushing Syndrome and Severe Adrenal Suppression Caused by Fluticasone and Protease
Inhibitor Combination in an HIV-Infected Adolescent.
 St Germain RM, Yigit S, Wells L, et al 
AIDS Patient Care STDS. 2007 Jun;21(6):373-7.
 Abstract
 
Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.
 Lankisch TO, Moebius U, Wehmeier M, et al 
Hepatology. 2006 Nov;44(5):1324-32.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 (Renal failure in a patient treated with atazanavir}
Moddel M, Pfammatter R, Varga Z, Keusch G. 
Schweiz Rundsch Med Prax. 2006 Jun 7;95(23):949-51.
 Abstract

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in
Combination with Zidovudine plus Lamivudine, in Antiretroviral-Naive HIV-Infected Patients.
Jemsek JG, Arathoon E, Arlotti M, et al
Clin Infect Dis. 2006 Jan 15;42(2):273-80.
 Abstract
 
Can boosted atazanavir induce hyperlipotrophy?
 Dellamonica P.  
 J Infect. 2005 Oct 17;
Abstract
 
Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.
 Brewster UC, Perazella MA. 
Am J Kidney Dis. 2004 Nov;44(5):e81-4
 Abstract

Does atazanavir cause lipodystrophy?
Gazzard BG, Moyle G.
J HIV Ther. 2004 May;9(2):41-4
 Abstract
Adherence
       
 
A WEEK-IN-REVIEW FEATURED REPORT
Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
 Petersen K, Riddle MS, Jones LE, et al